Juanolgar 3 mg lozenges with eucalyptus flavour
SpainTable of Contents
Package leaflet: Information for the user
Introduction
PACKAGE LEAFLET: INFORMATION FOR THE USER
Juanolgar 3 mg Lozenges with eucalyptus flavour
Hydrochloride bencidamine
Read the entire leaflet carefully before you start taking this medicine because it contains important information for you.
Follow exactly the instructions for use provided in this leaflet or those given by your doctor or pharmacist.
- Keep this leaflet, as you may need to read it again.
- If you need advice or more information, consult your pharmacist.
- If you experience any adverse reactions, consult your doctor or pharmacist, even if they are adverse reactions not listed in this leaflet. See section 4.
- You should consult a doctor if you worsen or do not improve after 3 days.
Contents of the leaflet:
-
What Juanolgar is and what it is used for
-
What you need to know before taking Juanolgar
-
How to take Juanolgar
-
Possible side effects
-
Storage of Juanolgar
-
Contents of the pack and other information
1. What Juanolgar is and what it is used for
Juanolgar contains the active substance benzidamine, a local anti-inflammatory agent belonging to the group of locally acting oral treatments.
Juanolgar is indicated in adults and children over 6 years of age for local symptomatic relief of pain and irritation of the mouth and throat.
You should consult a doctor if symptoms worsen or do not improve after 3 days.
2. What you need to know before taking Juanolgar
Do not take Juanolgar
- If you are allergic to benzydamine or any of the other ingredients of this medicine (listed in section 6).
Warnings and precautions
Talk to your doctor or pharmacist before taking Juanolgar
- If you have phenylketonuria.
- If you have had or currently suffer from asthma.
- If you are allergic to acetylsalicylic acid or to other non-steroidal anti-inflammatory analgesics (NSAIDs).
- If your doctor has told you that you have an intolerance to certain sugars, contact your doctor before taking this medicine.
- If mouth or throat pain worsens or persists for more than 3 days, if fever or other symptoms appear, and since in a limited number of patients, oropharyngeal ulcerations may be a sign of serious diseases, consult your doctor or dentist.
Taking Juanolgar with other medicines
Inform your doctor or pharmacist if you are using, have recently used, or might need to use any other medicines.
Taking Juanolgar with food and drinks
Food and drinks do not affect the use of this medicine.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, if you think you might be pregnant, or if you plan to become pregnant, consult your doctor or pharmacist before taking this medicine.
You must not use Juanolgar during pregnancy unless clearly necessary and advised by your doctor. If treatment is required, the lowest effective dose for the shortest possible duration should be used.
Juanolgar must not be taken during breastfeeding.
Driving and using machines
The use of Juanolgar does not affect the ability to drive or operate machinery.
Juanolgar contains:
Isomalt: if your doctor has diagnosed you with intolerance to certain sugars, consult him before taking this medicine.
Eucalyptus oil with d-limonene: may cause allergic reactions.
3. How to take Juanolgar
Follow exactly the dosage instructions provided in this leaflet or as directed by your doctor or pharmacist. If in doubt, consult your doctor or pharmacist.
The recommended dose is:
Adults and children over 6 years of age: 1 lozenge three times a day. Do not take more than 3 lozenges in 24 hours.
Use in children
Children aged 6 to 11 years: this medicine should always be administered under adult supervision.
The lozenge formulation must not be given to children under 6 years of age.
Juanolgar must not be taken for longer than 7 days.
How to take:
Oropharyngeal use.
Allow one lozenge to dissolve slowly in the mouth.
Do not swallow.
Do not chew.
If you take more Juanolgar than you should
If you accidentally take too many lozenges, contact your pharmacist, doctor, or the nearest hospital emergency department immediately. Always bring the medicine packaging with you, whether or not any lozenges remain.
Although very rare, reported overdose symptoms in children include excitement, seizures, sweating, gait disturbances, tremors, and vomiting after oral administration of doses approximately 100 times higher than a single lozenge dose.
If you have any further questions about the use of this product, consult your doctor or pharmacist.
In case of overdose or accidental ingestion of large amounts of Juanolgar, go immediately to a medical center or call the Toxicology Information Service at telephone number: 915.620.420, indicating the medicine and the amount ingested.
4. Possible adverse effects
Like all medicines, this medicine may cause adverse effects, although not everyone experiences them.
Uncommon (may affect up to 1 in 100 people):
- Skin sensitivity to sunlight (causing rash or sunburn).
Rare (may affect up to 1 in 1,000 people):
- Burning sensation or dryness of the mouth. If this occurs, try drinking a glass of water to reduce the effect.
Very rare (may affect up to 1 in 10,000 people):
- Sudden swelling of the mouth/throat and mucous membranes (angioedema).
- Difficulty breathing (laryngospasm).
Not known (frequency cannot be estimated from available data):
- Localized loss of sensitivity of the oral mucosa (oral hypoesthesia).
- Allergic reaction (hypersensitivity).
- Severe allergic reaction (anaphylactic reactions), which may include signs such as difficulty breathing, chest pain or tightness, and/or dizziness/fainting, intense itching of the skin or skin rashes, swelling of the face, lips, tongue, and/or throat, and which may be potentially fatal.
Reporting of adverse effects
If you experience any type of adverse effect, consult your doctor, pharmacist, or nurse, even if it is a possible adverse effect not listed in this leaflet. You can also report them directly via the Spanish Pharmacovigilance System for Human Medicines: www.notificaram.es. By reporting adverse effects, you can help provide more information on the safety of this medicine.
5. Storage of Juanolgar
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date stated on the packaging after the abbreviation EXP. The expiry date refers to the last day of the month indicated.
Do not store above 30°C.
Keep in the original packaging to protect from moisture.
Medicines must not be disposed of via wastewater or household waste. Dispose of unused medicines and their containers at the SIGRE Point at your pharmacy. If you are in doubt, ask your pharmacist how to properly dispose of unused medicines and their packaging. This way, you will help protect the environment.
6. Contents of the pack and other information
Composition of Juanolgar
- The active substance is bencidamine hydrochloride.
- Each pastille contains 3 mg of bencidamine hydrochloride (equivalent to 2.68 mg of bencidamine).
- The other components (excipients) are: isomalt (E953), potassium acesulfame, citric acid monohydrate, eucalyptus essential oil, levomenthol, quinoline yellow (E 104), indigo carmine (E132).
Appearance of the medicine and contents of the pack
This medicine is presented as square, dark green pastilles with a central cavity.
The pastilles may be packaged in PVC/PE/PVDC – ALU blisters or wrapped in paraffin paper.
Pack sizes: 20 or 30 pastilles.
Only certain pack sizes may be commercially available.
Marketing Authorization Holder
ANGELINI PHARMA ESPAÑA, S.L.
c/ Antonio Machado, 78-80
3rd floor, module A-Edificio Australia
08840 Viladecans, Barcelona (Spain)
Manufacturer
A.C.R.A.F. S.p.A.,
Via Vecchia del Pinocchio, 22
60131 – Ancona, Italy
This medicine is authorized in the European Economic Area member states under the following names:
Italy: Tantum Verde P, 3mg pastiglie gusto eucalipto
Spain: Juanolgar 3 mg Pastillas para chupar sabor eucalipto
Denmark: Zyx eucalyptus 3mg sugetabletter
Sweden: Zyx Eucalyptus 3 mg sugtabletter
United Kingdom: Difflam 3 mg Lozenges, eucalyptus flavour
This leaflet was last approved in April 2026
Detailed and up-to-date information on this medicine is available on the website of the Spanish Agency of Medicines and Health Products (AEMPS): http://www.aemps.gob.es/